Last Updated: May 31, 2026

List of Excipients in Branded Drug BASIC CARE COUGH DM


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for BASIC CARE COUGH DM

Last updated: March 9, 2026

What is the excipient profile of BASIC CARE COUGH DM?

BASIC CARE COUGH DM contains active ingredients dextromethorphan HBr (typical doses range from 10 mg to 20 mg per tablet or liquid dose) and guaifenesin (usually 100 mg per dose). The excipient composition generally includes:

  • Binders: Microcrystalline cellulose (used for tablet integrity)
  • Fillers: Lactose monohydrate
  • Disintegrants: Crospovidone or croscarmellose sodium
  • Lubricants: magnesium stearate
  • Flavoring agents: Various flavor oils or artificial flavors
  • Colorants: FD&C dyes (e.g., FD&C Red No. 40)

In liquid formulations, excipients such as propylene glycol, citric acid, and artificial sweeteners are common.

How do excipient choices impact formulating BASIC CARE COUGH DM?

Excipients influence drug stability, bioavailability, manufacturability, shelf life, and consumer experience. Key considerations:

  • Microcrystalline cellulose provides mechanical strength and controlled disintegration.
  • Lactose monohydrate acts as a filler but can cause issues for lactose-intolerant consumers.
  • Crospovidone enhances rapid disintegration, crucial for quick relief products.
  • Flavoring and coloring agents improve palatability, especially in pediatric formulations.

Manufacturers may adjust excipient types or sources to differentiate products or improve compliance with regulations like USP or EP standards.

What are the key commercial opportunities tied to excipient strategies?

Differentiation through formulation innovation

  • Developing lactose-free or gluten-free variants to expand consumer base.
  • Using natural flavorings or non-artificial colorants to target health-conscious demographics.
  • Incorporating organically sourced excipients to meet rising demand for clean-label products.

Regulatory advantage

  • Employing excipients with proven safety profiles (e.g., recognized Generally Recognized as Safe, or GRAS, status) eases regulatory approval.
  • Novel excipients can provide patentability or exclusivity if unique enough.

Manufacturing efficiencies and supply chain stability

  • Sourcing excipients from reliable suppliers to prevent shortages.
  • Standardizing excipient quality reduces batch variability, avoiding recalls.

Intellectual property and branding

  • Securing patents covering specific excipient formulations or combinations.
  • Branding products as "all-natural" or "lactose-free" enhances competitive positioning.

Cost management

  • Opting for cost-effective excipients without compromising quality.
  • Implementing scalable manufacturing processes that accommodate various excipient profiles.

What are the risks associated with excipient strategies?

  • Regulatory scrutiny over excipient use, especially novel or excipients not widely used in OTC products.
  • Consumer sensitivities, such as lactose intolerance or allergies to certain dyes.
  • Supply chain disruptions impacting critical excipients, affecting product availability.

How does regulatory landscape influence excipient choices?

Regulatory agencies, including the FDA, mandate detailed safety profiles for excipients used in OTC drugs. Approval depends on:

  • GRAS status of excipients.
  • Limits on excipient quantities per dose.
  • Clear labeling of excipient ingredients.
  • Documentation of manufacturing processes.

The recent trend favors natural, non-allergenic, and non-toxic excipients that meet these standards.

Summary table: Excipient options and commercial implications

Excipient Type Impact Commercial Opportunity
Microcrystalline cellulose Strong, binder, disintegrant Widely accepted, cost-effective
Lactose monohydrate Filler, disintegrant Differentiation via lactose-free variants
Croscarmellose sodium Rapid disintegration Enhances onset of action, competitive edge
Artificial flavoring Palatability Catering to flavor preferences
Natural flavoring Clean-label positioning Market for "natural" branding

Key considerations for formulation development

  • Prioritize excipients with established regulatory approval.
  • Consider consumer preferences (allergens, natural ingredients).
  • Balance cost with formulation stability and efficacy.
  • Innovate within regulatory constraints to expand product differentiations.

Key Takeaways

  • Excipient selection in BASIC CARE COUGH DM influences formulation efficacy, compliance, and consumer appeal.
  • Natural, allergen-free, and clean-label options present growth avenues.
  • Regulatory practices shape excipient choices, favoring safety and transparency.
  • Supply chain stability for key excipients mitigates market risks.
  • Innovation around excipient formulations offers opportunities for patenting and branding.

FAQs

1. Can changing excipients improve the marketability of BASIC CARE COUGH DM?
Yes. Using natural or allergen-free excipients can appeal to consumer trends and differentiate products in a crowded market.

2. Are there regulatory limits on excipient quantities in OTC products?
Yes. Agencies specify maximum allowable amounts, particularly for excipients that may cause intolerance or adverse reactions.

3. What excipients pose the greatest supply chain risk?
Excipients like lactose and certain colorants depend on centralized supply chains. Disruptions could impact manufacturing continuity.

4. Is patenting excipient formulations a common strategy?
It is possible for proprietary formulations, especially if involving novel excipients or unique combinations, to secure patent protection.

5. How might consumer preferences influence excipient choices?
Preferences for natural ingredients, allergen-free options, or minimal additives influence formulation decisions and product positioning.

References

  1. U.S. Food and Drug Administration (FDA). (2021). Guidance for industry: Excipients in drugs. [Online] Available at: https://www.fda.gov
  2. United States Pharmacopeia (USP). (2022). General chapter <467> Residual Solvent.
  3. European Pharmacopoeia (EP). (2022). Excipients standards and monographs.
  4. MarketWatch. (2023). OTC cough and cold products market analysis.
  5. IMS Health. (2022). Consumer trends in OTC medication formulations.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.